

ASX release

14 September 2017

Viking Yacht Company Adds SphygmoCor for Employee Wellness

AtCor Medical Holdings Limited (ASX:ACG), the developer and marketer of the SphygmoCor® system for advanced hypertension management, today announced that Viking Yacht Company, a leader in semi-custom fiberglass yacht production, has added AtCor Medical's SphygmoCor XCEL to its employee wellness program.

AtCor Medical CEO Duncan Ross said, "We are very pleased that SphygmoCor has become part of Viking Yacht's investment in employee health and wellbeing. While we have sold SphygmoCor to several executive health practitioners, this is our first sale to a corporate wellness program which allows all employees to benefit.

"Corporate wellness is an emerging part of the clinical market and, we believe, an important growth segment as companies seek to reduce employee absenteeism, illness and injuries. Employee wellbeing programs benefit productivity in the workplace and better health contributes to reducing healthcare costs for both employees and employers."

Through SphygmoCor, Viking Yacht Company employees receive access to leading technology for central blood pressure (the blood pressure at the heart) and arterial stiffness measurements which help to better inform their blood pressure management.

Viking Group Chairman and CEO Robert Healey, Sr. said: "We are proud of our employee wellness program. I decided to add SphygmoCor after benefiting from the technology through my personal physician. With this addition, we now have a more advanced tool to help our employees better understand their cardiovascular risk and they can use this important information to track results of lifestyle modifications and other interventions.

"Employee health is important for many reasons – for everything from personal health to corporate productivity. Our employees already have access to other advanced tests and an on-site healthcare professional. SphygmoCor is another example of a leading medical technology that will contribute to our employees' long-term health."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of target organ damage and management of cardiovascular and renal disease. Its technology allows researchers and clinicians to noninvasively measure the central arterial pressure waveform, central aortic pressures and pulse wave velocity. Central arterial pressure waveform analysis, as measured by the company's SphygmoCor® system, provides clinicians with better prognostic and diagnostic information to determine the need for and type of interventions, effects which cannot be detected with standard brachial blood pressure measurements. SphygmoCor® is essential for hypertension diagnosis and management.

More than 4,000 SphygmoCor® systems are currently in use worldwide at major medical institutions, research institutions and in various clinical trials with leading pharmaceutical companies. The company's technology has been featured in over 1,000 peer-reviewed studies published in leading medical journals and thousands of citations. AtCor Medical has operations in Australia, the United States, and Europe. For further information, please visit our web site at www.atcormedical.com.

About Viking Yacht Company

The Viking Yacht Company has celebrated over five decades in business building luxury performance sport fishing and cruising yachts. Started by brothers Bob and Bill Healy in 1964 when they bought Peterson-Viking Builders, a small, struggling New Jersey builder of 37-foot wooden sport fishing boats, Viking Yachts has grown to become a world leader in semi-custom fiberglass yacht production with over 4,000 Vikings delivered. Viking prides itself on renowned manufacturing capabilities. From the initial design to the finished product, Viking's highly-regarded reputation is rooted in the company's commitment to produce 90 percent of the boat in-house by its talented workforce.

For further information, please contact (AtCor):

Duncan Ross – AtCor Medical CEO
+1 (630) 228 8873

Peter Manley – AtCor Medical CFO
+61 (2) 8815 8811

Media enquiries to:

Ashley Rambukwella – Financial &
Corporate Relations
Ph: +61 (2) 8264 1004/ m. 0407 231 282
or a.rambukwella@fcr.com.au